About Trius Therapeutics
Trius Therapeutics is a company based in San Diego (United States) founded in 2004 was acquired by Cubist Pharmaceuticals in July 2013.. Trius Therapeutics has raised $69.16 million across 4 funding rounds from investors including Kleiner Perkins, Cubist Pharmaceuticals and FinTech Global Incorporated. Trius Therapeutics offers products and services including LLC Formation Guides and Service Reviews. Trius Therapeutics operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
- Headquarter San Diego, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$69.16 M (USD)
in 4 rounds
-
Latest Funding Round
$30.16 M (USD), Post-IPO
Jun 03, 2011
-
Investors
Kleiner Perkins
& 6 more
-
Employee Count
Employee Count
-
Acquired by
Cubist Pharmaceuticals
(Jul 30, 2013)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Trius Therapeutics
Trius Therapeutics offers a comprehensive portfolio of products and services, including LLC Formation Guides and Service Reviews. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Provides step-by-step instructions for starting LLCs in US states
Offers evaluations of legal and business formation services
Funding Insights of Trius Therapeutics
Trius Therapeutics has successfully raised a total of $69.16M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30.16 million completed in June 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $30.2M
-
First Round
First Round
(28 Feb 2007)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2011 | Amount | Post-IPO - Trius Therapeutics | Valuation |
investors |
|
| Nov, 2009 | Amount | Series B - Trius Therapeutics | Valuation |
investors |
|
| Mar, 2008 | Amount | Series B - Trius Therapeutics | Valuation | Kleiner Perkins |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Trius Therapeutics
Trius Therapeutics has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Kleiner Perkins, Cubist Pharmaceuticals and FinTech Global Incorporated. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech funding, drug development support, and investment in life sciences.
|
Founded Year | Domain | Location | |
|
Early-stage investing in IT and healthcare ventures.
|
Founded Year | Domain | Location | |
|
VC firm investing in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Trius Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Trius Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Trius Therapeutics Comparisons
Competitors of Trius Therapeutics
Trius Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| domain | founded_year | HQ Location |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| domain | founded_year | HQ Location |
Developer of bacterial ribosome-targeting drugs for MDR infections
|
|
| domain | founded_year | HQ Location |
Developer of antibiotics for MDR infections
|
|
| domain | founded_year | HQ Location |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
|
| domain | founded_year | HQ Location |
Therapeutics for antimicrobial resistant infections are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Trius Therapeutics
When was Trius Therapeutics founded?
Trius Therapeutics was founded in 2004 and raised its 1st funding round 3 years after it was founded.
Where is Trius Therapeutics located?
Trius Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Is Trius Therapeutics a funded company?
Trius Therapeutics is a funded company, having raised a total of $69.16M across 4 funding rounds to date. The company's 1st funding round was a Series B of $30M, raised on Feb 28, 2007.
What does Trius Therapeutics do?
Trius Therapeutics focuses on the discovery, development, and commercialization of antibiotics for serious infections. It developed tedizolid phosphate that has completed phase 3 clinical trial for the treatment of acute bacterial skin and skin structure infections and completed phase 1 clinical trial for the treatment of pneumonia. The tedizolid phosphate is a novel antibiotic for the treatment of serious Gram-positive bacterial infections, including those caused by methicillin-resistant staphylococcus aureus. The company also developed GyrBParE, which are in preclinical program and are targets of the fluoroquinolone class of antibacterial agents, such as ciprofloxacin It was acquired by Cubist Pharmaceuticals in July 2013.
Who are the top competitors of Trius Therapeutics?
Trius Therapeutics's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
What products or services does Trius Therapeutics offer?
Trius Therapeutics offers LLC Formation Guides and Service Reviews.
Who are Trius Therapeutics's investors?
Trius Therapeutics has 7 investors. Key investors include Kleiner Perkins, Cubist Pharmaceuticals, FinTech Global Incorporated, Sofinnova, and InterWest.